Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLF065 in Chronic Pouchitis
NCT07226050Phase 2Suspended
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of apraglutide in pouchitis, sponsored by Calibr-Skaggs Institute for Innovative Medicines. Started Jun 2026; status: suspended.
02
Drugs
apraglutide
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT07226050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226050.